Equities Analysts Offer Predictions for CMPX Q3 Earnings

Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) - Research analysts at Wedbush lowered their Q3 2025 earnings per share estimates for Compass Therapeutics in a note issued to investors on Tuesday, April 1st. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($0.13) for the quarter, down from their prior estimate of ($0.10). Wedbush currently has a "Outperform" rating and a $8.00 price target on the stock. The consensus estimate for Compass Therapeutics' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for Compass Therapeutics' Q4 2025 earnings at ($0.13) EPS, FY2025 earnings at ($0.49) EPS, FY2026 earnings at ($0.24) EPS and FY2027 earnings at $0.42 EPS.

A number of other research firms also recently weighed in on CMPX. Guggenheim restated a "buy" rating and issued a $12.00 price target on shares of Compass Therapeutics in a research note on Wednesday, April 2nd. Piper Sandler initiated coverage on shares of Compass Therapeutics in a research report on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price target for the company. Leerink Partnrs upgraded shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 1st. D. Boral Capital reaffirmed a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a report on Tuesday, April 1st. Finally, Leerink Partners raised Compass Therapeutics from a "market perform" rating to an "outperform" rating and boosted their price target for the stock from $4.00 to $6.00 in a report on Wednesday, April 2nd. Eight equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $13.38.

Compass Therapeutics Stock Performance

Compass Therapeutics stock traded up $0.17 during mid-day trading on Friday, reaching $1.76. The company's stock had a trading volume of 7,896,601 shares, compared to its average volume of 849,568. The business's 50 day simple moving average is $2.67 and its 200 day simple moving average is $2.10. The company has a market capitalization of $243.24 million, a price-to-earnings ratio of -4.74 and a beta of 1.40. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01).

Insider Activity

In other Compass Therapeutics news, insider Jonathan Anderman purchased 20,000 shares of the company's stock in a transaction dated Monday, April 7th. The stock was purchased at an average price of $1.54 per share, with a total value of $30,800.00. Following the completion of the purchase, the insider now owns 21,000 shares of the company's stock, valued at approximately $32,340. The trade was a 2,000.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 28.50% of the company's stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. MPM Bioimpact LLC grew its position in shares of Compass Therapeutics by 51.9% in the 4th quarter. MPM Bioimpact LLC now owns 8,567,896 shares of the company's stock valued at $12,423,000 after buying an additional 2,926,002 shares during the last quarter. Enavate Sciences GP LLC acquired a new position in shares of Compass Therapeutics in the fourth quarter worth approximately $11,293,000. Tang Capital Management LLC boosted its holdings in Compass Therapeutics by 225.4% in the fourth quarter. Tang Capital Management LLC now owns 5,900,000 shares of the company's stock valued at $8,555,000 after acquiring an additional 4,087,005 shares during the last quarter. Rock Springs Capital Management LP increased its position in Compass Therapeutics by 2.7% during the 4th quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company's stock valued at $8,380,000 after purchasing an additional 150,336 shares during the period. Finally, Blue Owl Capital Holdings LP raised its holdings in Compass Therapeutics by 2.6% during the 4th quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company's stock worth $4,284,000 after purchasing an additional 75,000 shares during the last quarter. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.